<!DOCTYPE html>
<html>

<head>
    <title>RWD Wall</title>
    <link rel="stylesheet" type="text/css" media="screen" href="css/styles.css" />
    <script src="js/jquery.min.js"></script>
    <script src="js/jquery.slides.js"></script>
    <!--<script src="js/attrchange.js"></script>-->
    <script src="/socket.io/socket.io.js"></script>
    <script src="js/receiver.js"></script>
</head>

<body>
    <section id="Container" class="Profile_1">
        <!--Slideshow container-->
        <div id="slides_container" class="test_hide">
            <div class="slides">
                <img src="images/Profile_1.jpg" alt="" class="Profile_1 current">
                <img src="images/Profile_2.jpg" alt="" class="Profile_2">
                <img src="images/Profile_3.jpg" alt="" class="Profile_3">
                <img src="images/Profile_4.jpg" alt="" class="Profile_4"> 
            </div>
        </div>
       
        <!--video section: both 'screensaver' and transition profile videos load here-->
        <div id="video_container" class="test_hide">
            <video class="Profile" id="Profile_1">
                <source src="video/Profile_1.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_2">
                <source src="video/Profile_2.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_3">
                <source src="video/Profile_3.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_4">
                <source src="video/Profile_4.mp4" type="video/mp4">
            </video>
        </div>

        <!--header is used for heading titles-->
        <header>
            <h2 class="preheader">From clinical trials to clinical practice:</h2>
            <h1>bring real-world data to life</h1>
        </header>

        <!--Profile sections-->
        <section id="Bio" class="Profile_1"></section>
        
        <section id="Patients">
            <ul>
                <li class="Profile_1"></li>
                <li class="Profile_2"></li>
                <li class="Profile_3"></li>
            </ul>
        </section>

        <!--Footer used for main footnotes-->
        <footer>
           <!--TODO: format footer here-->
            a Treatment-naïve HCV GT1 patients without cirrhosis may be considered for 8-week treatment with HARVONI.5 
            bEASL defines cure as SVR12.6
            c2% (31/1648) discontinued treatment early. This includes patients treated with 8, 12, 24 and other weeks of HARVONI ± RBV.1
            dEvidence of non-adherence was assessed upon the discretion of the investigators, and based on patient adherence to schedules and appointments, patient statements and congruence to the prescriptions.3
            1. Terrault N et al. Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study. Oral 94 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://www.natap.org/2015/AASLD/AASLD_04.htm. Accessed January 2016. 
            
            2. Curry MP et al. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster 1046 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://triohealth.com/wp-content/uploads/2015/11/Poster-Study-1-Final.pdf. Accessed January 2016. 3. Buggisch P et al. Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment. Poster 1205 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://www.aasld.org/sites/default/files/2015SupplementFULLTEXT.pdf. Accessed January 2016. 4. Christensen S et al. Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the German hepatitis C Cohort (GECCO).Poster 1081 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://www.aasld.org/sites/default/files/2015SupplementFULLTEXT.pdf. Accessed January 2016. 5. HARVONI Summary of Product Characteristics, January 2016. 6. European Association for the Study of the Liver (EASL). Recommendations on Treatment of Hepatitis C. J Hepatol 2015;63:199–236. 
        </footer>
    </section>


</body>

</html>